Printer Friendly

BARR REINTRODUCES ANTI-ANXIETY DRUG

 POMONA, N.Y., Sept. 22 /PRNewswire/ -- Barr Laboratories, Inc. (AMEX: BRL), announced today the reintroduction of Hydroxyzine Pamoate Capsules, USP 25mg, a generic equivalent to Pfizer's Vistaril(R).
 Barr and the FDA agree that the additional studies completed for Hydroxyzine Pamoate Capsules 25mg satisfy the FDA's validation requirements. Hydroxyzine Pamoate Capsules 25mg brings the number of products reintroduced under Barr Laboratories' revalidation program to a total of eight.
 The company is completing its validation study of Hydroxyzine Pamoate Capsules 100mg and expects its reintroduction by Nov. 1. the two products, Hydroxyzine Pamoate 25mg and 100mg, when last marketed, accounted for approximately $1 million in sales on an annualized basis.
 Hydroxyzine Pamoate is used to treat symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.
 Barr Laboratories is a manufacture of a broad range of generic pharmaceutical products with manufacturing facilities located in Northvale, N.J., and Pomona.
 -0- 8/22/93
 /CONTACT: Harold Cohen of Barr Laboratories, 914-362-2823/
 (BRL)


CO: Barr Laboratories, Inc. ST: New York IN: MTC SU: PDT

TW-SM -- NY019 -- 4589 09/22/93 10:21 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 22, 1993
Words:192
Previous Article:TEMCO SERVICE INDUSTRIES, INC. REPORTS THIRD QUARTER RESULTS
Next Article:ARMCO SELLS BRAZILIAN SHEET AND STRIP BUSINESS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters